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Abstract
Background: Human bocavirus (HBoV) is a newly identified human parvovirus. HBoV is associated with upper and lower
respiratory tract infections and gastroenteritis in children. Little is known about the seroepidemiology of HBoV in
populations in the Caribbean.
Methods: In a cross-sectional study conducted at the University Hospital of the West Indies in Kingston, Jamaica, 287 blood
samples were collected from pediatric patients and tested for the presence of HBoV-specific antibody using a virus-like-
particle based enzyme-linked immunosorbent assay (ELISA).
Results: HBoV-specific antibodies were found to be present in 220/287 (76.7%) of samples collected from the pediatric
population. Seroprevalence of HBoV was highest in those $2 years old. The seroepidemiological profile suggests that most
children are exposed to HBoV during the first two years of life in Jamaica.
Conclusion: HBoV infection is common in children in Jamaica. HBoV seroprevalence rates in the Caribbean are similar to
those previously reported in other areas of the world.
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Introduction
Lower respiratory tract infections, commonly caused by viruses,
are one of the leading causes of morbidity and mortality in
children worldwide [1]. In the United States, approximately
30,000 children each year are hospitalized during their first year of
life due to viral lower respiratory tract infections [2]. In developing
countries, the problem is even larger, where up to 1.8 million
children die each year due to acute respiratory illnesses [3].
Until recently, most viral lower respiratory infections in children
were attributed to respiratory syncytial virus (RSV), parainfluen-
zavirus, adenovirus, and influenza viruses [4,5]. Yet, while the
etiology of a majority of lower respiratory tract disease is thought
to be viral, only around 40% of cases have an etiologically
identifiable agent [6,7,8]. Over the last 10 years, advances in
molecular detection and genomic amplification have led to the
discovery of many new viruses including: human metapneumo-
virus (hMPV) [9]; human coronaviruses: NL63 [10] and HKU1
[11]; SARS-CoV [12], KI and WU polyomaviruses [13,14]; and
human bocavirus (HBoV) [15].
Herein we examine a novel respiratory virus, HBoV; a
parvovirus first described in 2005 by Allander et al. that has been
found to be associated with respiratory tract disease and
gastroenteritis in children [15]. Up to 4 different types of HBoV
have been isolated, with HBoV1 infecting primarily respiratory
epithelium and HBoV2-4 infecting the gastrointestinal tract
[16,17,18]. Clinical features associated with the detection of
HBoV1 infection include fever, rhinorrhea, cough, wheezing, and
gastroenteritis [16,17,18,19,20].
In the United States, HBoV viral DNA was detected by PCR in
5.2% of nasopharyngeal swabs from children in New Haven, CT
with respiratory tract disease who tested negative for RSV,
influenza A and B virus, parainfluenza viruses 1–3, and
adenoviruses, and 0% of asymptomatic control subjects, suggesting
a possible causal role for the virus in respiratory tract disease [19].
An additional seroepidemiology study in New Haven, CT found
that .90% of children had antibody to HBoV by the age of 4
years, suggesting exposure to HBoV is nearly universal in early
childhood [21]. Yet, little is known about HBoV in the developing
world.
In this study we sought to determine whether HBoV infection
was present in a Caribbean population, in an attempt to elucidate
possible differences in HBoV epidemiology in tropical resource
poor settings. Using a recently developed ELISA for HBoV [21],
we examined hospitalized and non-hospitalized children ages 0–18
years presenting for care at the University Hospital of the West
Indies, in Kingston, Jamaica between June 23 and August 10,
2009. The purpose of the study was to generate estimates of
exposure to HBoV in the Caribbean and to compare hospitalized
and non-hospitalized children of differing ages in an attempt to
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exposure.
Materials and Methods
This study was approved by the Yale University Human
Investigation Committee and the University Hospital of the West
Indies Investigation Committee. Written informed consent was
obtained from parents or guardians on behalf of the minors/
children participants involved in the study. A cross-sectional study
was conducted at the University Hospital of the West Indies,
located in Kingston, Jamaica from June 23, 2009 to August 10,
2009. Jamaica is a developing country with a population of 2.7
million, gross national income per captia of 4,870 USD’s and
infant mortality rate of 28 per 1000 live births [22]. The University
Hospital of the West Indies is the only academic medical center in
Jamaica, and serves as the primary public tertiary care center in
Jamaica.
Inclusion criteria for the study included all pediatric patients
aged 0–18 years of age presenting for care at the university
hospital. 287 total serum samples were collected from the pediatric
patient population. 118 (41%) samples were collected via finger-
stick method, with the use of the Stat Sampler
TM collecting system,
from children presenting for routine care and vaccination in well
child clinics. The remaining samples were collected from the
hospital’s clinical chemistry laboratory from left-over venipuncture
clinical sampling; including 77 (27%) from inpatient pediatric
units, 37 (12%) from pediatric subspecialty clinics, 25 (9%) from
the neonatal intensive care, 25 (9%) from pediatric trauma, and 5
(2%) from newborn special care. At the time of collection no
information on any symptomatology was collected, as the purpose
of the study was to screen for HBoV-specific IgG-antibody
representative of previous viral exposure. Both finger stick and
venous blood sampling was used as both have been shown to have
similar IgG rates in ELISAs, as shown by Vejtorp and Leerhoy
[23].
After collection, all blood samples were centrifuged at 10,000
RPM for 10 minutes, and blood serum was collected and stored.
Samples were stored at the University Hospital of the West Indies
at 220 degrees Celsius, prior to being shipped to Yale University
School of Medicine.
Detection of HBoV-specific antibodies in human serum
by HBoV Virus Like Particle–based ELISA
An ELISA developed by Kahn et al. was used to detect HBoV-
specific antibodies, a detailed description of which can be found
elsewhere [21]. Briefly, the ELISA uses virus like particles (VLPs)
composed of the VP2 gene of HBoV. The VLPs created by Kahn
et al. have shown high reactivity with human antibodies to HBoV,
and therefore are optimal for use in ELISAs. HBoV VLPs were
obtained from Dr. Peter Tattersall at Yale University School of
Medicine.
The Kahn et al. ELISA protocol was optimized for use with the
given study samples. First, samples were run at various dilutions to
determine the adequate dilution to use in the assay. A dilution of
1:40 was chosen for its optimal reactivity with HBoV VLPs in the
given ELISA. Next, positive and negative controls were identified
and compared to samples with known HBoV infection. The
identified positive and negative controls were used in each assay.
Finally, all 287 samples were run at a 1:40 dilution and read on an
optical reader at an optical density of 450 nm.
In order to determine a cut-off point to classify samples as
seropositive or seronegative all OD450 ELISA values were taken
and operationally separated into 2 groups by means of a cutoff of
0.150, as previously published by Kahn et al. [21] Next, the mean
and standard deviation of all values OD450,0.150 were
calculated. The cut off point to classify samples as seropositive
or seronegative was calculated as the mean of all OD450,0.150
plus three standard deviations. For this calculation, negative
OD450 values were set to zero. Based on these calculations, a
serum specimen negative for HBoV was defined as having an
OD450#0.234 (at dilution of 1:40).
Statistical Analysis
Data were analyzed with the use of SPSS 18.0. Standard errors
for proportions were calculated using standard statistical analysis.
Subjects with and without serologic evidence of past HBoV
infection were compared with respect to hospitalization status and
age group using chi-squared tests for categorical variables and t-
tests for continuous variables. Multivariate logistic regression was
used to determine significance in a final model. For all tests, a two-
tailed critical alpha of 0.05 defined statistical significance.
Results
287 blood samples were collected from pediatric patients aged
0–18 years at the University Hospital of the West Indies in
Kingston, Jamaica. The patients had a mean age of 50.13650.96
months (range of 0–236 months). 134 (46.7%) of the children were
male and 153 (53.3%) were female.
Overall, 220 (76.7%) of the 287 serum specimens were
seropositive for HBoV antibody. Proportion of seropositivity
varied by age group (Figure 1). Although 80% of newborns at
birth were seropositive for HBoV, this proportion decreased to
50% by six months of age. After six months of age the proportion
of seropositive subjects rapidly rebounded, so that by the age of 24
months .80% of children were seropositive. Age was a significant
predictor of HBoV exposure in all children (P,0.001), with HBoV
seropositive children being older (average age 30.3617.3 months)
than HBoV seronegative children (average age 17.8612.7 months)
In order to determine if hospitalization was associated with
HBoV exposure we characterized sub-groups of 84 hospitalized
children from the inpatient pediatrics wards and compared them
to 118 non-hospitalized children from the well child clinics (all of
whom had never previously been hospitalized). For these
comparisons all children from the sub-specialty clinics, neonatal
intensive care, pediatric trauma, and special care were excluded
on the basis of our inability to determine their previous
hospitalization history; and all neonates (,1 month) were also
excluded under the premise that a majority of positive values in
this age group would represent maternal antibody, not previous
HBoV exposure.
Hospitalization proved to be significantly associated with HBoV
exposure with 71/84 (84.5%) hospitalized children versus 79/118
(66.9%) of non-hospitalized children testing seropositive to HBoV
(P=0.005). However, hospitalized children were significantly
older with an average age of 53.2640.7 months versus
26.2616.9 months for non-hospitalized children (P,0.001). In a
multivariate analysis the age of the subjects proved to be the only
statistically significant finding.
Discussion
Seroepidemiology studies have been conducted in many
developed countries to screen for the presence of HBoV, and
the virus appears to have a worldwide distribution
[19,24,25,26,27,28]. To date there are very few reports on HBoV
from the developing world [29,30]. This study is the first
Bocavirus in Jamaica
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in a Caribbean population, with findings that greater than 80% of
Jamaican children are exposed to HBoV by the age of 24 months.
The seroepidemiology findings show a high rate of HBoV
antibody in the first month of life, with a decline to a nadir around
6 months and a rebound in seropositivity around 24 months. The
decline of antibody in infants less than 6 months of age represents
waning maternally acquired antibody, as observed in other
respiratory viruses such as RSV and human metapneumovirus
[31]. This decline overlaps with exposure to HBoV during infancy
and early childhood.
Age was the sole predictor associated with the presence of
HBoV antibody in the study population. HBoV exposure is
common in the population and therefore children have increasing
likelihood of exposure as their age increases. We enrolled both
healthy and hospitalized children in an effort to both characterize
the difference between exposure in these populations and to
adequately estimate HBoV seroepidemiology in the overall
population. Since HBoV seroepidemiology in subspecialty clinics
or hospitalized patients may not be representative of an overall
seropositivity rate of the population, we enrolled healthy children
in a prospective manner. While seroepidemiology in healthy vs
hospitalized children was different, with more hospitalized
children being exposed to HBoV than healthy children, this was
found to be directly related to the age of the populations.
Therefore, since the difference in the hospitalized and healthy
children was due to age we feel comfortable in including all the
children in the study in the overall estimation of the seroepide-
miolgoy of the population.
While HBoV seroepidemiology and prevalence studies have
shown evidence for widespread exposure to the virus, the causative
role of HBoV in respiratory tract disease is still under investiga-
tion. Definitive evidence is difficult to obtain without an in vitro
culture system and animal model. While there has been one recent
successful report of propagation of HBoV in cell culture, this
technique has proven difficult to replicate [32]. In the absence of
definitive evidence, comparative studies have been used to suggest
a causative role of HBoV in acute infection. However, these
studies are complicated by the fact that HBoV is often co-detected
with other respiratory viruses, which makes it difficult to draw
conclusions about its pathogenicity.
One study by Allander et al. showed that 5% of symptomatic
patients with acute wheezing tested positive for HBoV DNA by
PCR in the absence of 12 other viruses known to cause respiratory
disease [33]. This suggests a possible causative role for HBoV in
acute wheezing. Three other studies, by Kesebir, Fry and Maggi,
have also tried to address whether HBoV infection was associated
with respiratory tract symptoms. These studies reported that
HBoV DNA was more frequently found in patients with acute
respiratory tract symptoms than asymptomatic controls
[19,30,34].
Limitations of our study included lack of serial sampling, lack of
detection of viral DNA by PCR, and our inability to verify our
ELISA findings with a neutralization assay. Currently, one of the
Figure 1. Seroepidemiology of HBoV shown by age group. The no. of serum samples screened and the percentage of seropositive individuals
are shown for each age group; bars indicate standard errors.
doi:10.1371/journal.pone.0038206.g001
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HBoV is the lack of reagents, specifically infectious virus and
monospecific anti-HBoV antibodies [32]. Therefore, we were
unable to verify our ELISA with a neutralization assay. Instead,
we used accepted statistical methods for correct cut-off values in
ELISAs [21]. Regrettably, our study was performed prior to the
discovery that HBoV has specific subtypes. The ELISA used is not
specific to individual HBoV subtypes but rather to HBoV-specific
antibodies in general, making the findings not a statement
specifically on HBoV1, but of all HBoV subtypes.
In conclusion, this is the first study of HBoV seroepidemiology
in a Caribbean population. We showed that HBoV is a common
virus infecting children within the first few years of life. Our
findings of HBoV seroepidemiology in Jamaica are similar to
reports from other areas of the world, reinforcing the notion that
HBoV has a worldwide distribution.
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